This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...

Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

java-core project provides vast interview programs, Real time implementation, Exceptions, regular expressions, collections, oops concepts ect. Here you can gain the knowledge about java syntax, ...

President Trump has delayed imposing tariffs on pharmaceuticals to allow for more negotiations with drug companies.Francis Chung/Bloomberg News The Trump administration says it doesn't plan to impose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

WASHINGTON, DC - APRIL 2: President Donald Trump signs an executive order imposing tariffs on imported goods during a "Make America Wealthy Again" trade announcement event in the Rose Garden at the ...

Have you ever wondered how Java seamlessly combines its primitive data types with object-oriented programming? Enter wrapper classes, an important but often overlooked Java feature. These special ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...